Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Angiogenesis is critical for hepatocellular carcinoma (HCC) development.
• Targeting angiogenesis is a promising strategy for HCC treatment.

Purpose of the Study:

• To investigate the anti-angiogenic effects of the natural compound deguelin on HCC.
• To elucidate the molecular mechanisms underlying deguelin's action in HCC.

Main Methods:

• In vitro assays using human umbilical vascular endothelial cells (HUVECs) to assess proliferation, migration, invasion, and tube formation.
• In vivo studies using patient-derived HCC xenografts.
• Analysis of VEGF and c-Met signaling pathways.

Main Results:

• Deguelin inhibited VEGF-induced HUVEC proliferation, migration, invasion, and tube formation.
• Deguelin reduced tumor angiogenesis in vivo and decreased VEGF autocrine in HCC cells.
• Deguelin suppressed HGF-induced c-Met activation, impacting VEGF production.

Conclusions:

• Deguelin exhibits significant anti-angiogenic properties against HCC.
• Deguelin acts by inhibiting VEGF signaling in endothelial cells and reducing proangiogenic factors in cancer cells.
• Deguelin demonstrates therapeutic potential for HCC treatment.